Fosun Pharma USA Inc. (“Fosun Pharma USA”) announced today its abstract on ASTRIDE (NCT05468489), a phase 3 randomized, open-label study of serplulimab vs atezolizumab both in combination with chemotherapy (Carboplatin-Etoposide) in patients with extensive-stage small-cell lung cancer (ES-SCLC), has been accepted for presentation at the International Association for the Study of Lung Cancer’s (IASLC) 2023 North America Conference on Lung Cancer (NACLC).
|
[28-November-2023] |
PRINCETON, N.J., Nov. 28, 2023 /PRNewswire/ -- Fosun Pharma USA Inc. (“Fosun Pharma USA”) announced today its abstract on ASTRIDE (NCT05468489), a phase 3 randomized, open-label study of serplulimab vs atezolizumab both in combination with chemotherapy (Carboplatin-Etoposide) in patients with extensive-stage small-cell lung cancer (ES-SCLC), has been accepted for presentation at the International Association for the Study of Lung Cancer’s (IASLC) 2023 North America Conference on Lung Cancer (NACLC), being held in Chicago, Illinois, Dec. 1 - 3, 2023. All abstracts accepted for presentation have been published on the NACLC website. “Our PIs are excited to present their poster on the design of the ASTRIDE Trial in Progress (TiP), which is an important milestone for the lead investigators and authors,” said Stan Lechpammer, Vice President, Medical Affairs, Innovative Medicines, Fosun Pharma USA. “This presentation provides greater insight into the ASTRIDE trial that investigates serplulimab as a potentially new therapeutic option for extensive-stage (ES) small-cell lung cancer patients (SCLC). SCLC is an aggressive malignancy, with the majority of patients presenting with extensive-stage disease at initial diagnosis. There is a high unmet need for this patient population. Beyond the potential of our TiP study design, we have committed to recruiting patients from many medically underserved communities, to address health disparities and improve health equity for ES-SCLC patients in the U.S.” Abstract accepted for presentation’s details and key points about the study design:
Key Highlights about Study Design
About Serplulimab About the ASTRIDE Phase 3 Trial About Small-cell Lung Cancer About Fosun Pharma USA Created as an entrepreneurial business entity, Fosun Pharma USA is a U.S.-focused specialty pharmaceutical company, innovating through strategic partnerships and building its commercial presence in the United States. Fosun Pharma USA leverages its global parent company, Fosun Pharma Group, as well as a unique R&D model, to advance innovative products to patients in need. Fosun Pharma USA is led by a team of highly experienced executives, who have a strong track record as leaders at both U.S. and European-based pharma companies, in both commercial operations and R&D. Its current portfolio is comprised of specialty pharmaceutical injectable products and ophthalmics, to build a portfolio of high value, branded innovative products. The company is continuing to build its pipeline with late development stage (phase 2 and beyond) or commercial stage innovative products for the U.S. market, primarily. While Fosun Pharma USA can facilitate a partnership with Fosun HQ for the Chinese market, the focus is on U.S. rights for innovative biopharmaceutical products. Website: www.fosunpharmausa.com; Follow us on LinkedIn for more company updates: Fosun Pharma USA Inc. Fosun Pharma USA Forward-Looking Statement Fosun Pharma USA Contacts: Media or Investors: View original content:https://www.prnewswire.com/news-releases/fosun-pharma-usa-announces-abstract-to-be-presented-at-iaslc-2023-north-america-conference-on-lung-cancer-naclc-301999521.html SOURCE Fosun Pharma USA |